乳腺癌患者内分泌治疗诱导的脱发
这项回顾性队列研究纳入112例乳腺癌患者,分析内分泌治疗诱导的脱发(EIA)的临床特征、生活质量影响及米诺地尔疗效。脱发模式类似雄激素性脱发,多数为轻度,但生活质量情绪领域受显著负面影响;局部米诺地尔治疗后46例中37例(80%)中度或显著改善。
要点
- EIA模式类似雄激素性脱发,绝大多数(96/104,92%)为1级轻度脱发。
- 芳香化酶抑制剂相关75例(67%),他莫昔芬相关37例(33%)。
- 毛发镜特征以毳毛及中等和粗直径终毛干为主。
核心结论
- 内分泌治疗相关脱发模式类似雄激素性脱发,与致病药物的作用机制一致。
- 尽管脱发严重程度多为轻度,患者报告生活质量受到显著负面影响。
研究设计与样本
- 回顾性队列研究,纳入2009年1月1日至2016年12月31日在一家大型三级医院和综合癌症中心皮肤科确诊EIA的112例乳腺癌患者。
- 评估临床特征、脱发相关生活质量(Hairdex问卷,0-100分,评分越高生活质量越低)及米诺地尔疗效。
- 米诺地尔疗效由单盲研究者通过头皮标准化临床照片在3或6个月时评估。
主要发现
- 共纳入112例女性乳腺癌患者,中位年龄60岁(范围34-90岁)。
- 104例(93%)有标准化临床照片;其中59例(53%)有基线毛发镜图像,46例(41%)评估了米诺地尔反应。
- 脱发归因于芳香化酶抑制剂75例(67%),他莫昔芬37例(33%)。
- 104例中96例(92%)为1级,模式类似雄激素性脱发;基线毛发镜主要特征为毳毛及中等和粗直径终毛干。
- Hairdex评分显示生活质量负面影晌,情绪领域效应更高(均值[SD] 41.8[21.3];P<.001);局部米诺地尔治疗后46例中37例(80%)中度或显著改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Endocrine therapy-induced alopecia (EIA) has been anecdotally reported but not systematically described. OBJECTIVE: To characterize EIA in patients with breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 112 patients with breast cancer, diagnosed with EIA from January 1, 2009, to December 31, 2016, the patients were examined at the dermatology service in a large tertiary care hospital and comprehensive cancer center. MAIN OUTCOMES AND MEASURES: The clinical features, alopecia-related quality of life (QoL), and response to minoxidil of EIA in patients with breast cancer were assessed. Data from the Hairdex Questionnaire was used to assess the impact of the alopecia on patients QoL. Higher score indicates lower QoL (0-100 score). Efficacy of minoxidil was measured at 3 or 6 months by a single-blinded investigator through standardized clinical photographs of the scalp. RESULTS: A total of 112 female patients with breast cancer were included (median [range] age, 60 [34-90] years). A total of 104 patients (93%) had standardized clinical photographs; of these, 59 patients (53%) had trichoscopy images available at baseline, and 46 patients (41%) were assessed for response to minoxidil. Alopecia was attributed to aromatase inhibitors in 75 patients (67%) and tamoxifen in 37 (33%). Severity was grade 1 in 96 of 104 patients (92%), and the pattern was similar to androgenetic alopecia. The predominant trichoscopic feature at baseline was the presence of vellus hairs and intermediate- and thick-diameter terminal hair shafts. A negative impact on QoL was reported, with a higher effect in the emotion domain according to the Hairdex score (mean [SD], 41.8 [21.3]; P < .001). After treatment with topical minoxidil, moderate or significant improvement in alopecia was observed in 37 of 46 patients (80%). CONCLUSIONS AND RELEVANCE: Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents. A significant negative impact on QoL was reported by patients, despite mostly mild alopecia severity.
引用
- Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. JAMA Dermatol. 2018. PMID: 29641806. doi:10.1001/jamadermatol.2018.0454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。